Cargando…

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review

Background: Pompe disease is a lysosomal storage disease characterised by skeletal and respiratory muscle weakness. Since 2006, enzyme replacement therapy (ERT) with alglucosidase alfa has been available. ERT significantly improves the prognosis of patients with Pompe disease. The effect of high ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ditters, Imke A. M., van Kooten, Harmke A., van der Beek, Nadine A. M. E., van der Ploeg, Ans T., Huidekoper, Hidde H., van den Hout, Johanna M. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526476/ https://www.ncbi.nlm.nih.gov/pubmed/37759814 http://dx.doi.org/10.3390/biom13091414

Ejemplares similares

Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
por: van Kooten, Harmke A., et al.
Publicado: (2022)

MRI changes in diaphragmatic motion and curvature in Pompe disease over time
por: Harlaar, Laurike, et al.
Publicado: (2022)

Broad variation in phenotypes for common GAA genotypes in Pompe disease
por: Niño, Monica Y., et al.
Publicado: (2021)

Chest MRI to diagnose early diaphragmatic weakness in Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2021)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Hearing in adults with Pompe disease
por: van der Beek, Nadine A. M. E., et al.
Publicado: (2011)

Diffusion tensor imaging of the brain in Pompe disease
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
por: van der Wal, Erik, et al.
Publicado: (2017)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study
por: Yuan, Meng, et al.
Publicado: (2020)

GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
por: van der Wal, Erik, et al.
Publicado: (2017)

Burden of illness of Pompe disease in patients only receiving supportive care
por: Kanters, Tim A., et al.
Publicado: (2011)

Long-term benefits of physical activity in adult patients with late onset Pompe disease: a retrospective cohort study with 10 years of follow-up
por: Ismailova, Gamida, et al.
Publicado: (2023)

Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease
por: Mackenbach, Maarten J., et al.
Publicado: (2023)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Phenotypical variation within 22 families with Pompe disease
por: Wens, Stephan C A, et al.
Publicado: (2013)

The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In Vivo
por: Murray, Allen K.
Publicado: (2020)

Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
por: Poelman, Esther, et al.
Publicado: (2020)

Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience
por: Niño, Monica Y., et al.
Publicado: (2020)

Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis
por: in ’t Groen, Stijn L.M., et al.
Publicado: (2020)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Extension of the Pompe mutation database by linking disease‐associated variants to clinical severity
por: Niño, Monica Y., et al.
Publicado: (2019)

Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients
por: van den Dorpel, J. J. A., et al.
Publicado: (2020)

IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy
por: Liang, Qiushi, et al.
Publicado: (2022)

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients
por: van Capelle, Carine I., et al.
Publicado: (2011)

Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease
por: Harlaar, Laurike, et al.
Publicado: (2019)

PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease
por: Hagemans, Marloes L. C., et al.
Publicado: (2010)

Association of Muscle Strength and Walking Performance in Adult Patients With Pompe Disease
por: Favejee, Marein M, et al.
Publicado: (2018)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

A conceptual disease model for adult Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2015)

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease
por: Kuperus, Esther, et al.
Publicado: (2018)

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany
por: Schoser, Benedikt, et al.
Publicado: (2015)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Newborn screening for pompe disease? a qualitative study exploring professional views
por: van El, Carla G, et al.
Publicado: (2014)

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
por: van Gelder, Carin M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ji576g8cag3ugq6vs00k1j0sjb